

## *In vitro* Cytotoxic Pentacyclic Triterpenoids of *Newbouldia laevis*

<sup>1</sup>P.A. Onocha, <sup>1</sup>D.A. Okorie, <sup>2</sup>H.C. Krebs and <sup>2</sup>B. Meier

<sup>1</sup>Department of Chemistry, University of Ibadan, Ibadan, Nigeria

<sup>2</sup>Zafur Chemie Analytik and Endokrinologie, Der Tierarztlichen Hochschule,  
Bischofsholer Damm 15, 30173 Hannover, Germany

**Abstract:** Bioactivity directed fractionation afforded four cytotoxic constituents from the bioactive methanolic leaf extract ( $LD_{50}$  30  $\mu\text{g mL}^{-1}$ ) of *Newbouldia laevis* (Bignoniaceae) collected from Ibadan, Nigeria. Four pentacyclic triterpenoids namely  $2\alpha$ ,  $3\beta$ ,  $19\alpha$ -trihydroxy-12-ursen-28-oic acid,  $3\beta$ ,  $19\alpha$ -dihydroxy-12-ursen-28-oic acid,  $3\beta$ -hydroxy-12-ursen-28-oic acid,  $3\beta$ -hydroxy-12-oleanen-28-oic acid were found to be the cytotoxic principles. These compounds demonstrated significant cytotoxicity *in vitro* against ST-57 brain tumor transformed fibroblasts with  $LD_{50}$  ranging from 0.4  $\mu\text{g mL}^{-1}$  (compound 1) to 4  $\mu\text{g mL}^{-1}$  (compound 4). These ursene and oleanene type triterpenoids are encountered for the first time in this plant. The structures of these compounds were established by spectral data.

**Key words:** Bignoniaceae, fibroblasts, cytotoxicity, bioactivity, ursenoic acid, oleanenoic acid

### INTRODUCTION

In a continuing collaborative search for naturally occurring medicinal agents from plants, the leaves of *Newbouldia laevis* (Beauv.) Seem. ex Bureau (Bignoniaceae) collected from Ibadan, Nigeria were selected for investigation. Previous phytochemical reports on this species were on the root, root bark, flowers and stem. *N. laevis* is a common tree of West African origin well known for its ethno medical uses. The leaves, bark, stem and roots are used in the treatment of conjunctivitis, arthritis, dysentery, enlarged spleen, heart burn, wounds, ear and stomach ache, sore feet, chest pain, epilepsy and children's convulsion (Burkill, 1985, 2000; Oliver-Bever, 1986; Iwu, 2000). The anti-inflammatory, antipyretic, analgesic and anticonvulsant properties of the stem bark and flowers have been studied (Olajide *et al.*, 1997; Usman *et al.*, 2008; Tanko *et al.*, 2008a). Different parts of the plant has also been shown to exhibit antimicrobial, antimalarial, sedative, anti-inflammatory, antinociceptive, anti-diabetic, uterine contractile and antioxidant properties (Gafner *et al.*, 1996; Amos *et al.*, 2002; Eyong *et al.*, 2005; Kuete *et al.*, 2007; Usman and Osuji, 2007; Tanko *et al.*, 2008a, b; Ogunlana and Ogunlana, 2008; Bafor and Sammi, 2009; Ainooson *et al.*, 2009; Bafor *et al.*, 2010; Oloyede *et al.*, 2010).

Recent phytochemical analysis of the root, root bark and stem of this plant afforded alkaloids, quinoids, ceramides and phenylpropanoids amongst others (Adesanya *et al.*, 1994; Houghton *et al.*, 1994;

Aladesanmi *et al.*, 1998; Gafner *et al.*, 1996, 1997, 1998; Gormann *et al.*, 2003, 2006; Eyong *et al.*, 2005, 2006; Kuete *et al.*, 2007).

There was no extensive report on the isolation of compounds from the leaves (Usman and Osuji, 2007). Bioassay-guided fractionation of the leaf methanolic extract of *N. laevis* afforded four cytotoxic pentacyclic triterpenoids which are encountered for the first time in the plant.

This study therefore, reports the isolation of four triterpenoids namely  $2\alpha$ ,  $3\beta$ ,  $19\alpha$ -trihydroxy-12-ursen-28-oic acid or tormentic acid,  $3\beta$ ,  $19\alpha$ -dihydroxy-12-ursen-28-oic acid or pomolic acid,  $3\beta$ -hydroxy-12-ursen-28-oic acid or Bungeolic acid,  $3\beta$ -hydroxy-12-oleanen-28-oic acid or Astrantiagenin-C as cytotoxic constituents of the leaf methanolic extract of *N. laevis* (Fig. 1).




Fig. 1: Cytotoxic constituents of the leaf methanolic extract of *N. laevis*

## MATERIALS AND METHODS

**General methods:** All melting points were determined on a Kofler hot stage apparatus and are uncorrected. IR and UV spectra were recorded on a Pelkin Elmer model 983. Mass spectra were determined on an MS9025 Mass spectrometer.  $^1\text{H}$  and  $^{13}\text{C}$ -NMR including 2D-NMR, DEPT spectra were recorded on a Bruker WP300SY Spectrometer (300.133 MHz for  $^1\text{H}$  and 75.468 MHz for  $^{13}\text{C}$ ).

**Plant materials:** The leaves of *N. laevis* collected from Jericho forest reserve, Ibadan, Nigeria was authenticated at source and confirmed by Mr. Felix Usang at the Forest Research Institute of Nigeria where a voucher specimen (No. KH1106427) was deposited in the herbarium.

**Extraction and isolation:** The air dried leaves of *N. laevis* (800 g) were ground and soxhlet extracted first with hexane for 48 h to afford the hexane extract (34.3 g) and subsequently with methanol to yield the methanolic extract (76.6 g, ST-57, LD<sub>50</sub> 30  $\mu\text{g mL}^{-1}$ ). A portion of the methanol extract (30 g) was subjected to dry flash column (8×10 cm) chromatography on silica gel (230-400 mesh). Gradient elution of the column started with light petroleum (40-60°C) followed by increasing percentages of light petroleum (5, 10 and 15%). Fractions obtained were analysed by silica gel TLC and combined on the basis of similar TLC profiles to give 10 major fractions (NL01-NL10). Compounds were detected by UV light (254 nm), I<sub>2</sub> absorption or Vanillin-H<sub>2</sub>SO<sub>4</sub> spray reagent. Subsequently, further investigations were only on the bioactive fractions (NL 6-8).

Fraction NL08 (250 mg, LD<sub>50</sub> 10  $\mu\text{g mL}^{-1}$  *in vitro* against ST-57 brain tumor transformed fibroblasts) was obtained from 90% EtOAc in light petroleum and after repeated column and flash chromatographic separation yielded compound 1 which was recrystallised from methanol-acetone giving a white solid (mp 264-266°). On structural elucidation and comparison with reference data (Doddrell *et al.*, 1974; Numata *et al.*, 1989; Lontsi *et al.*, 1990; Rahman and Ahmad, 1994), compound 1 was resolved as 2 $\alpha$ , 3 $\beta$ , 19 $\alpha$ -trihydroxy-12-ursen-28-oic acid or tormentic acid.

Fraction NL07 (250 mg, LD<sub>50</sub> 15  $\mu\text{g mL}^{-1}$  *in vitro* against ST-57 brain tumor transformed fibroblasts) was eluted from 85% EtOAc in hexane yielding compound 2 as pure white crystalline substance on repeated column chromatographic separation. It was recrystallized from methanol-acetone (mp 280-82°). On structural elucidation and comparison with reference data (Kuang *et al.*, 1989; Guang-Yi *et al.*, 1989; Soares *et al.*, 1998), the structure of compound 2 was deduced as 3 $\beta$ , 19 $\alpha$ -dihydroxy-12-ursen-28-oic acid or pomolic acid.

Fraction NL06 (336 mg, LD<sub>50</sub> 20  $\mu\text{g mL}^{-1}$  *in vitro* against ST-57 brain tumor transformed fibroblasts) was obtained from 85% EtOAc in hexane as a greenish solid which was purified in similar manner to NL08 giving compound 3 as a white crystalline solid (mp 277° {Decomp}). Compound 3 was identified as 3 $\beta$ -hydroxy-12-ursen-28-oic acid or bungeolic acid by spectral data and comparison with reference data (Connolly and Hill, 1991; Rahman and Ahmad, 1994).

Fraction NL06 (336 mg, LD<sub>50</sub> 20  $\mu\text{g mL}^{-1}$  *in vitro* against ST-57 brain tumor transformed fibroblasts) was obtained as a greenish substance from 85% EtOAc in hexane. Repeated column chromatographic, LH 20 Sephadex (33% chloroform in methanol) separation and recrystallization from acetone-methanol mixture, yielded compound 4 as a white crystalline solid (mp 272° {Decomp.}) compound 4 was identified as 3 $\beta$ -hydroxy-12-oleanen-28-oic acid or Astrantiagenin-C by spectral data and comparison with reference data (Numata *et al.*, 1989; Connolly and Hill, 1991; Rahman and Ahmad, 1994).

### Spectral data

#### Compound 1:

- IR  $\nu_{\text{max}}$  cm<sup>-1</sup> (KBr): 3577-2940 br (OH and COOH), 1688 (acid)
- HRMS m/z (rel.int.%): 488.077 (0.7, M<sup>+</sup>, C<sub>30</sub>H<sub>48</sub>O<sub>5</sub>)
- EIMS 70 eV: 264(100), 249(36.5, 264-CH<sub>3</sub>), 219(18, 264-COOH), 223 (15.5)
- $^1\text{H}$ NMR (C<sub>5</sub>D<sub>5</sub>N, 300.133 MHz):  $\delta$  5.55 (1H, t, J = 3.5, H-12), 4.09 (1H, dt, J = 6, 9 Hz, H-2 $\beta$ ), 3.38 (1H, d, J = 9Hz, H-3), 3.12 (1H, dt, J = 13.5 Hz, H-16 $\alpha$ ), 3.04 (1H, s; H-18), 2.3 (2H, d, J = 6 Hz; H-1), 2.28 (1H, dt, J = 13, 4 Hz, H-15 $\beta$ ), 2.25 (1H, dt, J = 13, 5 Hz, H-16 $\beta$ ), 1.95 (1H, dt, J = 13.5 Hz, H-15 $\alpha$ ), 1.70 (3H, s, 29-Me), 1.42 (3H, s, 27-Me), 1.26 (3H, s, 23-Me), 1.12 (3H, d, J = 6 Hz, 30-Me), 1.09 (3H, s, 26-Me), 1.07 (3H, s, 24-Me), 1.01 (3H, s, 25-Me)
- $^{13}\text{C}$ NMR (C<sub>5</sub>D<sub>5</sub>N, 75.468 MHz (Table 1):  $\delta$  180.7 (C-28), 140.0 (C-13), 127.9 (C-12), 84.0 (C-3), 72.9 (C-19), 68.6 (C-2), 56.0 (C-5), 54.6 (C-18), 48.3 (C-17), 47.9 (C-1), 47.6 (C-9), 42.4 (C-14), 42.2 (C-20), 40.4 (C-8), 39.8 (C-4), 38.5 (C-22), 38.5 (C-10), 33.5 (C-7), 29.3 (C-23), 26.9 (C-21), 29.1 (C-29), 26.4 (C-16), 29.3 (C-15), 24.7 (C-27), 24.1 (C-11), 19.0 (C-6), 17.7 (C-26), 17.3 (C-30), 16.9 (C-25), 16.8 (C-24)

#### Compound 2:

- IR  $\nu_{\text{max}}$  cm<sup>-1</sup> (pyridine): 3600-3300 br (OH and COOH), 1697 (acid)
- HRMS m/z (rel.int.%): 472.177 (0.87, M<sup>+</sup>, C<sub>30</sub>H<sub>48</sub>O<sub>4</sub>)
- EIMS 70 eV: 390 (M<sup>+</sup>-COOH-(H<sub>2</sub>O)<sub>2</sub>), RDA fragment of ring C, 264 (100), 249 (25.5, 264-CH<sub>3</sub>), 219 (11.264-COOH), 207 (25.5)

Table 1: <sup>13</sup>CNMR of compounds 1-4

C	δ: <sup>13</sup> CNMR (C <sub>5</sub> D <sub>5</sub> N, 75.468 MHz) of compounds			
	1	2	3	4
1	47.9	38.9	38.5	38.8
2	68.6	28.0	27.1	28.0
3	84.0	78.1	77.2	78.0
4	39.8	39.3	38.2	37.3
5	56.0	55.8	54.3	55.7
6	19.0	18.8	20.1	18.7
7	33.5	35.5	35.8	33.1
8	40.4	40.3	39.0	39.6
9	47.6	47.7	47.0	48.0
10	38.5	37.3	37.8	37.2
11	24.1	23.9	23.2	23.6
12	127.9	128.0	125.5	122.4
13	140.0	139.9	138.1	144.7
14	42.4	42.0	38.6	39.3
15	29.3	29.2	27.0	28.2
16	26.4	26.3	24.4	23.6
17	48.3	48.2	46.4	46.4
18	54.6	54.5	51.8	41.9
19	72.9	72.6	38.1	42.1
20	42.2	42.3	38.6	30.8
21	26.9	26.8	32.1	34.1
22	38.5	38.4	35.9	37.2
23	29.3	28.7	28.6	28.7
24	16.8	17.1	14.3	15.6
25	16.9	16.4	14.7	16.5
26	17.7	16.7	16.0	17.3
27	24.7	24.6	22.2	26.0
28	180.7	180.6	180.9	180.1
29	29.1	27.0	29.9	33.1
30	17.3	15.5	17.3	23.6

- <sup>1</sup>HNMR (C<sub>5</sub>D<sub>5</sub>N, 300.133 MHz): δ 5.62 (1H, t, J = 3.5 Hz, H-12), 3.41 (1H, t, J = 9 Hz, H-3α), 3.14 (1H, dt, J = 13.5 Hz, H-16α), 3.05 (1H, s; H-18), 2.35 (1H, dt, J = 13.5 Hz, H-15β), 2.24 (1H, dt, J = 13.5 Hz, H-16β), 2.08 (1H, m; H-15α), 1.87 (2H, m; H-2), 1.72 (3H, s; Me-29), 1.44 (3H, s, Me-27), 1.21 (3H, s, Me-24), 1.10 (3H, d, J = 6 Hz, Me-30), 1.10 (3H, s, Me-26), 1.02 (3H, s, Me-23), 0.90 (3H, s, Me-25)
- <sup>13</sup>CNMR (C<sub>5</sub>D<sub>5</sub>N, 75.468 MHz (Table 1): δ: 180.6 (C-28), 139.9 (C-13), 128.0 (C-12), 78.1 (C-3), 72.6 (C-19), 55.8 (C-5), 54.5 (C-18), 48.2 (C-17), 47.7 (C-9), 42.0 (C-14), 40.3 (C-8), 39.3 (C-4), 38.9 (C-1), 38.4 (C-22), 37.3 (C-10), 35.5 (C-7), 42.3 (C-20), 29.2 (C-15), 28.7 (C-23), 28.0 (C-2), 27.0 (C-29), 26.8 (C-21), 26.3 (C-16), 24.6 (C-27), 23.9 (C-11), 18.8 (C-6), 17.1 (C-24), 16.7 (C-26), 16.4 (C-25), 15.5 (C-30)

**Compound 3:**

- IR  $\nu_{\max}$  cm<sup>-1</sup> (KBr): 3430-2920 br (OH and COOH), 1695 (acid)
- HRMS m/z (rel.int.%): 456.606 (3.22, M<sup>+</sup>, C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>),
- EIMS 70 eV: RDA fragment of ring C, 248 (100), 203 (48.8, 248-COOH), 207 (25.25)

- <sup>1</sup>HNMR (C<sub>5</sub>D<sub>5</sub>N, 300.133 MHz): δ 5.23 (1H, t, J = 3.5 Hz, H-12), 3.50 (1H, t, J = 9 Hz, H-3α), 2.18 (1H, d, J = 3.5, H-18), 1.82 (2H, m; H-2), 1.80 (2H, dt, J = 13.5 Hz, H-16), 1.27 (6H, d, J = 6 Hz; Me-29, 30), 1.17 (2H, dt, J = 10.3, 4.3 Hz, H-15), 0.97 (3H, s, Me-27), 0.93 (3H, s, Me-23), 0.92 (3H, s, Me-25), 0.89 (3H, s, Me-24), 0.86 (3H, s; Me-26)
- <sup>13</sup>CNMR (C<sub>5</sub>D<sub>5</sub>N, 75.468 MHz (Table 1): δ 180.9 (C-28), 138.1 (C-13), 125.5 (C-12), 77.2 (C-3), 54.3 (C-5), 51.8 (C-18), 47.0 (C-9), 46.4 (C-17), 39.0 (C-8), 38.6 (C-20), 38.6 (C-14), 38.5 (C-1), 38.2 (C-4), 38.1 (C-19), 37.8 (C-10), 35.9 (C-22), 35.8 (C-7), 32.1 (C-21), 29.9 (C-29), 28.6 (C-23), 27.1 (C-2), 27.0 (C-15), 24.4 (C-16), 23.2 (C-11), 22.2 (C-27), 20.1 (C-6), 17.3 (C-30), 16.0 (C-26), 14.7 (C-25), 14.3 (C-24)

**Compound 4:**

- IR  $\nu_{\max}$  cm<sup>-1</sup> (KBr): 3500-2941 br (OH and COOH), 1689 (acid)
- HRMS m/z (rel.int.%): 456.007 (1.55, M<sup>+</sup>, C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>)
- EIMS 70 eV: RDA fragment of ring C, 248 (100), 233 (4.18, M<sup>+</sup>-CH<sub>3</sub>), 207 (25.25, M<sup>+</sup>-COOH), 203 (16)
- <sup>1</sup>HNMR (C<sub>5</sub>D<sub>5</sub>N, 300.133 MHz): δ 5.48 (1H, t, J = 3.5 Hz, H-12), 3.45 (1H, t, J = 7 Hz; H-3α), 3.29 (1H, t, J = 3.5 Hz, H-18), 1.82 (2H, m, H-2), 1.80 (1H, dd, J = 13.5 Hz, H-16α), 1.27 (3H, s; Me-27), 1.23 (3H, s; Me-23), 1.17 (1H, dd, J = 13, 4.5, H-15β), 1.0 (3H, s; Me-26), 1.0 (3H, s; Me-25), 0.98 (3H, s; Me-29), 0.92 (3H, s; Me-30), 0.85 (3H, s; Me-24)
- <sup>13</sup>CNMR (C<sub>5</sub>D<sub>5</sub>N, 75.468 MHz (Table 1): δ 180.1 (C-28), 144.7 (C-13), 122.4 (C-12), 78.0 (C-3), 55.7 (C-5), 48.0 (C-9), 46.4 (C-17), 42.1 (C-19), 41.9 (C-18), 39.6 (C-8), 39.3 (C-14), 38.8 (C-1), 37.3 (C-4), 37.2 (C-22), 37.2 (C-10), 34.1 (C-21), 33.1 (C-29), 33.1 (C-7), 30.8 (C-20), 28.7 (C-23), 28.2 (C-15), 28.0 (C-2), 26.0 (C-27), 23.6 (C-30), 23.6 (C-16), 23.6 (C-11), 18.7 (C-6), 17.3 (C-26), 16.5 (C-25), 15.6 (C-24)

**Cytotoxicity assay:** The *in vitro* cytotoxicity assay were carried out to the standard protocols established by the National Cancer Institute (Geran *et al.*, 1972). Different concentration (4 and 0.4 μg mL<sup>-1</sup>) of the compounds were tested *in vitro* against ST-57 brain tumor transformed fibroblasts.

Primary culture of fibroblasts was prepared by method of explantate culture (Meier *et al.*, 1990a, b). Fibroblasts were cultured as mono layers on all to a confluency (5 × 10<sup>4</sup> cells cm<sup>-2</sup>) on plastic strips in a 4 well multiwell. The cells were inoculated in 2 mL medium containing the compounds (dissolved in methanol and diluted with 0.1 phosphate buffer saline) in sterile atmosphere in multiwells. Control cells contained

Table 2: Cytotoxicity of compounds 1-4 against brain tumor transformed fibroblasts

Compounds	LD 50 $\mu\text{g mL}^{-1}$						
	0.04	0.1	0.2	0.4	1	2	4
1	-	-	-	+++	+++	+++	+++
2	-	-	-	-	++	+++	+++
3	-	-	-	-	-	++	+++
4	-	-	-	-	-	-	++
Control	-	-	-	-	-	-	-
Adriamycin	+++	+++	+++	+++	+++	+++	+++

+++ : Good activity; +: Low activity; ++: Moderate activity; -: No activity

methanol and phosphate buffer saline. Cytotoxicity was appreciated by evaluation of LD<sub>50</sub> values up to the 3rd day of treatment. LD<sub>50</sub> value  $\leq 4 \mu\text{g mL}^{-1}$  for pure compounds are considered significant. Results are shown in Table 2.

## RESULTS AND DISCUSSION

In an initial study, the methanol extract of *N. Laevis* was found to be cytotoxic when tested *in vitro* against ST-57 brain tumor transformed fibroblasts (LD<sub>50</sub> 30  $\mu\text{g mL}^{-1}$ ). As a result of subjecting this methanol extract to flash column and Sephadex LH 20 chromatography on silica gel and cytotoxic assay, three (NL 06, NL 07, NL 08) of the ten combined fractions were found to demonstrate significant cytotoxic activity (ST 57, LD<sub>50</sub> < 20  $\mu\text{g mL}^{-1}$ ). Fractions NL 08 and NL 07 yielded compounds 1 and 2, respectively while fraction NL 06 yielded compounds 3 and 4.

Compound 1 exhibited a molecular formula of C<sub>30</sub>H<sub>48</sub>O<sub>4</sub> based on its high resolution EIMS data. It gave rise to IR absorption bands for a carboxylic acid and a vinyl bond at  $\nu_{\text{max}}$  1688 and 1640  $\text{cm}^{-1}$ , respectively in addition to the observed bands at 3300-2900 (OH, COOH). The <sup>13</sup>CNMR displayed signals for 30 carbon atoms: one carbonyl ( $\delta$  180.6), two ethylenic carbon atoms (-C=C-,  $\delta$  127.9 and 140.0), two oxymethine, an oxygen bearing quaternary carbon, ( $\delta$  72.9), seven methyls, eight methylene, four methines and five quaternary carbon atoms. Six methyls were tertiary and the olefinic proton gave a signal at  $\delta$  5.55. The signal for H 18 was a broad singlet indicating its  $\beta$ -diposition relative to the D-ring (Doddrell *et al.*, 1974). The presence of the double bond at C-12 was confirmed by the chemical shifts at  $\delta$  127.9 (C-12) and  $\delta$  139.9 (C-13), characteristic of  $\Delta^{12}$  urs 12 enes (Doddrell *et al.*, 1974). Six tertiary methyl at  $\delta$  1.01, 1.07, 1.09, 1.26, 1.42, 1.70 (each, 3 H, s) and a secondary methyl at  $\delta$  1.12 (3H, d, 30-Me) are indicative of a pentacyclic ursene triterpene (Doddrell *et al.*, 1974). Since, in ursene skeleton, the proton at C-18 appeared as a singlet, the tertiary hydroxy group could only be located at C-19. The

two secondary carbinol protons resonated at  $\delta$  3.38 (1 H, d, J = 9 Hz) and 4.09 (1 H, dt, J = 6.9 Hz) indicating that both were neighbours coupling with each other (J = 9 Hz) while the doublet of triplet was in addition coupled to two other neighbouring protons (J = 6 Hz). Based on these deductions, the one proton doublet was assigned to C-3 with the neighbouring carbinol proton at C-2. This was in accordance with the <sup>13</sup>C-nmr resonances observed at  $\delta$  84.0 and 68.6. The value of the coupling constants and carbon resonances confirm that the hydroxy group is attached  $\beta$  to C-3 (J = 9 Hz) and strongly deshielded hence, the high resonance of  $\delta$  84.0 observed while the other hydroxyl group is attached  $\alpha$  to C-2 and shielded thereby resonating at  $\delta$  68.6. These value are consistent with reference data (Connolly and Hill, 1991). From comparison of the <sup>1</sup>HNMR and <sup>13</sup>CNMR of compound 1 with reference data (Kuang *et al.*, 1989; Numata *et al.*, 1989), the structure of compound 1 was identified as 2 $\alpha$ , 3 $\beta$ , 19 $\alpha$ -trihydroxy-12-ursen-28-oic acid or tormentic acid.

Compound 2 exhibited a molecular formula of C<sub>30</sub>H<sub>48</sub>O<sub>4</sub>, based on its high resolution EIMS data. It gave rise to IR absorption bands for a carboxylic acid and a vinyl bond at  $\nu_{\text{max}}$  1697 and 1640  $\text{cm}^{-1}$ , respectively. The <sup>13</sup>CNMR with DEPT spectrum revealed 30 carbon signals including characteristic signals due to a trisubstituted double bond- $\delta$  128.0 (d) and 140.0 (s), one carbonyl ( $\delta$  180.6), one oxymethine, an oxygen bearing quaternary carbon ( $\delta$  72.6), seven methyls, nine methylene, four methines and five quaternary carbon atoms. The difference between compound 1 and 2 was mainly the absence of one oxymethine which was evident in the low  $\delta$  value of C-2 (28.0). Based on these and comparison with compound 1 and reference data (Kuang *et al.*, 1989; Guang-Yi *et al.*, 1989), compound 2 was identified as 3 $\beta$ , 19 $\alpha$ -dihydroxy-12-ursen-28-oic acid or pomolic acid.

Compound 3 exhibited a molecular formula of C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>, based on its high resolution EIMS data. It gave rise to IR absorption band at  $\nu_{\text{max}}$  3430-2920  $\text{cm}^{-1}$  (OH and COOH), 1695 (acid) 1695  $\text{cm}^{-1}$ . The <sup>13</sup>CNMR gave signals for 30 carbon atoms, one carbonyl ( $\delta$  180.6), two ethylenic carbon atoms (-C=C-,  $\delta$  125.5 and 138.1), one oxymethine, seven methyls, nine methylene, four methines and five quaternary carbon atoms. The structure of compound 4 was deduced based on its spectral properties and comparison with reference data (Numata *et al.*, 1989; Rahman and Ahmad, 1994). Comparison of the spectral data (IR, MS, NMR) with those of 3 $\beta$ -hydroxy-12-ursen-28-oic acid or Bungeolic acid confirmed that they were the same compound.

Compound 4 exhibited a molecular formula of C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>, based on its high resolution EIMS data. It gave rise to IR absorption bands at  $\nu_{\text{max}}$   $\text{cm}^{-1}$  (KBr): 3500-2941

br (OH and COOH), 1689 (acid). <sup>13</sup>CNMR gave signals for 30 carbon atoms: one carbonyl ( $\delta$  180.6), two ethylenic carbon atoms ( $\delta$  125.5 and 138.1), one oxymethine, seven methyls, nine methylene, four methines and six quaternary carbon atoms. The structure of compound 4 was deduced based on its spectral properties and comparison with reference data (Rahman and Ahmad, 1994; Spengel, 1996). Comparison of the spectral data (IR, MS, NMR) with those of 3 $\beta$ -hydroxy-12-oleanen-28-oic acid or Astrantiagenin-confirmed that they were the same compound.

These compounds were tested for their cytotoxicity and found to possess significant cytotoxicity against ST 57 brain tumor transformed fibroblasts. Compound 1 was the most active (LD<sub>50</sub> 0.4  $\mu$ g mL<sup>-1</sup>) while compound 4 (LD<sub>50</sub> 4  $\mu$ g mL<sup>-1</sup>) was the least active (Table 2). The presence of hydroxy group appears to have some effect on the activity as the activity was observed to increase as the number of hydroxy groups in the molecule increased from compound 4 to compound 1.

### CONCLUSION

Although, extensive research had been done on the root, stem and flowers of *N. laevis*, limited research has been carried out on the leaves of the plant (Usman and Osuji, 2007). This report therefore, establishes the cytotoxicity of the leaf methanolic extract. In addition, four of the compounds responsible for cytotoxic antitumor activity of the leaf methanolic extract has been identified, isolated and characterised. To the best of the knowledge, there is no prior report of the presence of terpenoids in the plant.

### ACKNOWLEDGEMENT

P.A.O. is grateful to the Deutscher Akademischer Austauschdienst (DAAD) for a fellowship to Chemisches Institut Der Tierärztlichen Hochschule, Hannover for this study.

### REFERENCES

Adesanya, S.A., R. Nir, C. Fontaine and M. Pais, 1994. Pyrazole alkaloids from *Newbouldia laevis*. *Phytochemistry*, 15: 1053-1055.

Ainooson, G.K., E. Woode, D.D. Obri and G.A. Koffour, 2009. Antinociceptive effects of *Newbouldia laevis* (P. Beauv.) Stem bark extract in a Rat model. *Pharmacogn. Mag.*, 5: 49-54.

Aladesanmi, A.J., R. Nia and A. Nahrstedt, 1998. New pyrazole alkaloids from the root bark of *Newbouldia laevis*. *Planta Med.*, 64: 90-91.

Amos, S., L. Binda, H. Vongtau, B. Chindo and J. Abbah *et al.*, 2002. Sedative effects of the methanolic leaf extract of *Newbouldia laevis* in mice and rats. *Boll. Chim. Farm.*, 141: 471-475.

Bafor, E. and U. Sami, 2009. Uterine contractile effects of the aqueous and ethanol leaf extracts of *Newbouldia laevis* (Bignoniaceae) *in vitro*. *Indian J. Pharm. Sci.*, 71: 124-127.

Bafor, E.E., U. Sami and Z.A. Nworgu, 2010. *In vitro* determination of the mechanism of the uterine stimulatory effect of *Newbouldia laevis*. *Pharm. Biol.*, 48: 808-815.

Burkill, H.M., 1985. *The Useful Plants of West Tropical Africa*. Kew Publishing, Charlottesville VA., pp: 258.

Burkill, H.M., 2000. *The Useful Plants of West Tropical Africa*. Vol. 5, Royal Botanical Gardens, Kew.

Connolly, J.D. and R.A. Hill, 1991. *Methods in Plant Biochemistry*. Vol. 7, Academic Press, London, pp: 331-359.

Doddrell, D.M., P.W. Khong and K.G. Lewis, 1974. The stereochemical dependant of <sup>13</sup>C chemical shift in olean-12-enes and urs-12-enes as an aid to structural assignment. *Tetradrom. Lett.*, 27: 238-284.

Eyong, K.O., G.N. Folefoc, V. Kuete, V.P. Beng and K. Krohn *et al.*, 2006. Newbouldiaquinone A: A naphthoquinone-anthraquinone ether coupled pigment, as a potential antimicrobial and antimalarial agent from *Newbouldia laevis*. *Phytochemistry*, 67: 605-609.

Eyong, K.O., K. Krohn, H. Hussain, G.N. Folefoc, A.E. Nkengfack, B. Schulz and Q. Hu, 2005. Newbouldiaquinone and Newbouldiamide: A new naphthoquinone-anthraquinone coupled pigment and a new ceramide from *Newbouldia laevis*. *Chem. Pharm. Bull.*, 53: 616-619.

Gafner, S., J.L. Wolfende, M. Nianga and K. Hostettmann, 1997. Phenylpropanoid glycosides from *Newbouldia laevis* roots. *Phytochemistry*, 44: 687-690.

Gafner, S., J.L. Wolfender, M. Nianga and K. Hostettmann, 1998. A naphthaquinone from *Newbouldia laevis* root. *Phytochemistry*, 48: 215-216.

Gafner, S., J.L. Wolfender, M. Nianga, H. Stoeckli-Evans and K. Hostettmann, 1996. Antifungal and antibacterial naphthaquinones from *Newbouldia laevis* roots. *Phytochemistry*, 42: 1315-1320.

Geran, R.I., N.H. Greenberg, N.M. Macdonald, A.M. Schumacher and B.J. Abbott, 1972. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. *Cancer Chem. Rep.*, 3: 51-61.

Gormann, R., M. Kaloga, D. Ferreira, J.P. Marais and H. Kolodziej, 2006. Newbouldiosides A-C, phenylethanoid glycosides from the stem bark of *Newbouldia laevis*. *Phytochemistry*, 67: 805-811.

- Gormann, R., M. Kaloga, X.C. Li, D. Ferreira, D. Bergenthal and H. Kolodziej, 2003. Furanonaphthaquinones, atraric acid and a benzofuran from the stem barks of *Newbouldia laevis*. *Phytochemistry*, 64: 583-587.
- Guang-Yi, L., A.I. Gray and P.G. Waterman, 1989. Pentacyclic triterpenes from the fruits of *Rosa sterilis*. *J. Nat. Prod.*, 52: 162-166.
- Houghton, P.J., P. Rite and J.E. Hawkes, 1994. Naphthaquinones and an alkaloid from roots of *Newbouldia laevis*. *Phytochemistry*, 35: 1602-1603.
- Iwu, M.M., 2000. *Handbook of African Medicinal Plants*. CRC Press Inc., London, Pages: 19.
- Kuang, H.X., R. Kasai, K. Ohtani, Z.S. Liu, C.S. Yuan and O. Tanaka, 1989. Chemical constituents of pericarps of *Rosa davurica* Pall, a traditional Chinese medicine. *Chem. Pharm. Bull.*, 37: 2232-2233.
- Kuete, V., K.O. Eyong, G.N. Folefoc, V.P. Beng, H. Hussain, K. Krohn and A.E. Nkengfack, 2007. Antimicrobial activity of the methanolic extract and of the chemical constituents isolated from *Newbouldia laevis*. *Pharmazie*, 62: 552-556.
- Lontsi, D., B.L. Sondengam, J.F. Ayafor, M.G. Tsoupras and R. Tabacchi, 1990. Further triterpenoids of *Musanga cecropioides*: The structure of cecropic acid. *Planta Med.*, 56: 287-289.
- Meier, B., H.H. Radeke, S. Selle, G.G. Habermehl, K. Resch and H. Sies, 1990b. Human fibroblasts release low amounts of reactive oxygen species in response to the Potent phagocyte stimulants, serum-treated zymosan, N-formyl-methionyl-leucyl-phenylalanine, leukotriene B4 or 12-O-tetradecanoylphorbol 13-acetate. *Biol. Chem. Hoppe. Seyler*, 37: 1021-1025.
- Meier, B., H.H. Radeke, S. Selle, H.H. Raspe, H. Sies, K. Resch and G.G. Habermehl, 1990a. Human fibroblasts release reactive oxygen species in response to treatment with synovial fluids from patients suffering from arthritis. *Free Rad. Res. Commun.*, 8: 149-160.
- Numata, A., P. Yang, C. Takahashi, R. Fujiki, M. Nabae and E. Fujita, 1989. Triterpenoids from *Psidium guajava*. *Chem. Pharm. Bull.*, 37: 648-648.
- Ogunlana, O.E. and O.O. Ogunlana, 2008. *In vitro* assessment of antioxidant activity of *Newbouldia laevis*. *J. Med. Plants Res.*, 2: 176-179.
- Olajide, O.A., S.O. Awe and J.M. Makinde, 1997. Pharmacological studies on *Newbouldia laevis* stem bark. *Fitoterapia*, 68: 439-443.
- Oliver-Bever, B., 1986. *Medicinal Plants in Tropical West Africa*. Cambridge University Press, UK., ISBN: 9780521268158, pp: 117-168.
- Oloyede, G.K., P.A. Onocha, J. Soyinka, O. Oguntokun and E. Thonda, 2010. Phytochemical screening, antimicrobial and antioxidant activities of four Nigerian medicinal plants. *Ann. Biol. Res.*, 2: 114-120.
- Rahman, A.U. and V.U. Ahmad, 1994. *Handbook of Natural Products Data: Pentacyclic Triterpenoids*. Elsevier Publishers, Tokyo, ISBN: 9780444882004, pp: 800-890.
- Soares, F.P., C.A.V. Ranconi, E.V.L. da Cunha, J.M. Barbosa-Filho, M.S. da Silva and R. Braz-Filho, 1998. Four known triterpenoids isolated from three Brazilian plants: 1H and 13C chemical shift assignments. *Mag. Res. Chem.*, 36: 608-614.
- Spengel, S.M., 1996. Two pentacyclic triterpenes from *Phytolacca dodecandra* roots. *Phytochemistry*, 43: 179-182.
- Tanko, Y., B. Kamba, M.I.A. Saleh, K.Y. Musa and A. Mohammed, 2008a. Anti-nociceptive and anti-inflammatory activities of ethanolic flower extract of *Newbouldia laevis* in mice and rats. *Int. J. Applied Res. Natl. Prod.*, 1: 13-19.
- Tanko, Y., M.A. Okasha, M.I.A. Saleh, A. Mohammed, M. Yerima, A.H. Yaro and A.I. Isa, 2008b. Anti-Diabetic effect of ethanolic flower extracts of *Newbouldia laevis* (Bignoniaceae) on blood glucose levels of Streptozocin-induced diabetic Wistar rats. *Res. J. Med. Sci.*, 2: 57-60.
- Usman, H. and J.C. Osuji, 2007. Phytochemical and *in vitro* antibacterial assay of the leaf extract of *Newbouldia laevis*. *Afr. J. Trad. CAM*, 4: 476-480.
- Usman, H., A.H. Yaro and M.M. Garba, 2008. Phytochemical and Anticonvulsant screening of the ethanolic extracts of *Newbouldia laevis* (Bignoniaceae) in mice. *J. Pharm. Tox.*, 3: 127-133.